-Treatment-Market-Size.jpg)
Myeloproliferative Disorders Treatment Market size was over USD 9.34 billion in 2023 and is projected to cross USD 14.42 billion by the end of 2036, witnessing more than 3.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of myeloproliferative disorders treatment is estimated at USD 9.59 billion.
The increasing investments in research and development activities along with rising incidences of myeloproliferative disorders is predicted to boost the market growth. Furthermore, the rising awareness for molecular abnormalities and cellular pathways associated with the MPN pathogenesis is expected to facilitate the development of clinical trials and novel drugs, which is estimated to boost the market growth. There is no known cure for this disorder, so the treatment is focused on treating the symptoms, which include weight loss, pale skin, blood clotting and excessive blood loss, splenomegaly, cachexia, and others. This raises the scope for R&D activities for developing novel drugs and treatment methods for this disorder, which is estimated to boost the market growth.
Growth Drivers
Restraints
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
3.4% |
|
Base Year Market Size (2023) |
USD 9.34 billion |
|
Forecast Year Market Size (2036) |
USD 14.42 billion |
|
Regional Scope |
|
The market is segmented by type, treatment, and by end-user. Based on end-user, the market is segmented into hospitals, home care, specialty clinics, and others out of which hospital segment is anticipated to hold the largest market share throughout the forecast period. This can be attributed to growing healthcare facilities and a rising number of hospitals along with the increasing incidences of myeloproliferative disorders globally. Similarly, the segment for specialty clinics is also expected to grow at a significant rate over the forecast period as a result of the increasing number of specialized and disease-specific clinics which is estimated to boost the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End-User |
|
Based on the regional analysis, the global myeloproliferative disorders treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The market in the North America region is estimated to hold the largest market share in the market over the forecast period owing to the undergoing advanced research and development in the healthcare sector along with the presence of leading pharmaceutical companies conducting innovative clinical experiments. The market in the Europe region is projected to garner significant revenue during the forecast period owing to the development of novel treatment options, high demand for targeted therapies, and increasing geriatric population in the region.
There is no known cure for the myeloproliferative disorder, however, there are various drugs and treatments to improve the symptoms and prolong the patient’s life. Major companies, developing these drugs, include,
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?